Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845023 · ClinicalTrials.gov registry record · Phase 2
Trial of AD036 in Obstructive Sleep Apnea
A Phase 2 study of Obstructive Sleep Apnea, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 12
- Study locations
NCT03845023 is a Phase 2 study of Obstructive Sleep Apnea that has completed, run by Apnimed. The registered enrollment target is 140 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (37% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT03845023, a Phase 2 study of Obstructive Sleep Apnea, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a randomized, double blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient phase 2 clinical study to examine the efficacy and safety of three dose levels of AD036 versus placebo in patients with obstructive sleep apnea.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AD036 Dose 1
- DRUG AD036 Dose 2
- DRUG AD036 Dose 3
Study Locations (12)
California
- Stanford Sleep Medicine - Redwood City
- SDS Clinical Trials, Inc. - Santa Ana
- Santa Monica Clinical Trials - Santa Monica
Arizona
- Pulmonary Associates - Glendale
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Illinois
- Northwestern University - Chicago
Kentucky
- Norton Clinical Research Group - Louisville
Maryland
- The Center for Sleep and Wake Disorders - Chevy Chase
Missouri
- Sleep Medicine & Research Center, St. Luke's Hospital - Chesterfield
New York
- Clinilabs Drug Development Corporation - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845023
The ClinicalTrials.gov registry entry for NCT03845023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (37% lower). The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03845023 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03845023 about?
NCT03845023 is a clinical study titled "Trial of AD036 in Obstructive Sleep Apnea". This is a randomized, double blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient phase 2 clinical study to examine the efficacy and safety of three dose levels of AD036 versus placebo in patients with obstructive sleep apnea.
What is the current status of trial NCT03845023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2019-03-07. Estimated completion is 2019-10-23.
What conditions does trial NCT03845023 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT03845023?
The interventions under investigation include: Placebo (DRUG), AD036 Dose 1 (DRUG), AD036 Dose 2 (DRUG), AD036 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT03845023?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845023 being conducted?
This trial has 12 study locations across Arizona, Arkansas, California, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
RECRUITING · Phase 2
-
Down Syndrome Obstructive Sleep Apnea
RECRUITING · Phase 2
-
Dexmedetomidine Versus Propofol Sedation for Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.